Pricing

Cyclacel Pharmaceuticals Inc (CYCC)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Spiro Rombotis
Employees:
14
200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ, 07922
908-517-7330
    Formally known as:
  • Xcyte Therapies Inc.
Stock Split History
DateRatio
2006-03-27 1:1
2012-08-27 1:7
2016-05-31 1:12
2020-04-15 1:20
2023-12-18 1:15
Cyclacel Pharmaceuticals, Inc. develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) and CYC140. Sapacitabine, a nucleoside analog that is orally available prodrug of CNDAC, is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available